ArticleThe journal of pain2016
An Evaluation of Central Sensitization in Patients With Sickle Cell Disease.
Article in The journal of pain, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03899246 (Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease), which is not on this map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant.British journal of haematology · 2019Trial
- Mixed pain phenotypes in musculoskeletal disorders: mechanisms and management.Nature reviews. Rheumatology · 2026Review
- Simplified Procedure for Isolation and Culture of Neuronal Cells from Brains of Sickle Cell Mice.Cells · 2026Article
- Informed shared decision-making or rigid eligibility and exclusion criteria for gene therapy for sickle cell disease?Blood advances · 2026Review
- The relation between sleep and pain sensitization in pediatric sickle cell disease.Journal of pediatric psychology · 2026Article
- Chronic pain in the aging adult with sickle cell disease.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease.Blood advances · 2025Review
- Genetic Modifiers Associated with Vaso-Occlusive Crises and Acute Pain Phenomena in Sickle Cell Disease: A Scoping Review.International journal of molecular sciences · 2025Article
- Elevated posterior insula glutamate in patients with sickle cell disease.The journal of pain · 2025Article
- Pain sensitisation in patients with sickle cell disease: A preliminary study.Journal of evaluation in clinical practice · 2025Article
- Impact of dental caries on the quality of life of children with sickle cell anaemia in Nigeria.Journal of public health in Africa · 2025Article
- Increased Delta and Theta Power Density in Sickle Cell Disease Individuals with Chronic Pain Secondary to Hip Osteonecrosis: A Resting-State Eeg Study.Brain topography · 2024Article
- Genetic contributions to pain modulation in sickle cell: A focus on single nucleotide polymorphisms.Gene reports · 2024Article
- Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease.Blood advances · 2024Article
- Brain network hypersensitivity underlies pain crises in sickle cell disease.Scientific reports · 2024Article
- Altered pain processing and sensitization in sickle cell disease: a scoping review of quantitative sensory testing findings.Pain medicine (Malden, Mass.) · 2024Article
- Inflammation and autoimmunity are interrelated in patients with sickle cell disease at a steady-state condition: implications for vaso-occlusive crisis, pain, and sensory sensitivity.Frontiers in immunology · 2024Article
- Mouse models of sickle cell disease: Imperfect and yet very informative.Blood cells, molecules & diseases · 2024Review
- Cold exposure induces vaso-occlusion and pain in sickle mice that depend on complement activation.Blood · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
unlabelledCentral sensitization (CS), nociceptive hyperexcitability known to amplify and maintain clinical pain, has been identified as a leading culprit responsible for maintaining pain in several chronic pain conditions. Recent evidence suggests that it may explain differences in the symptom experience of individuals with sickle cell disease (SCD). Quantitative sensory testing (QST) can be used to examine CS and identify individuals who may have a heightened CS profile. The present study categorized patients with SCD on the basis of QST responses into a high or low CS phenotype and compared these groups according to measures of clinical pain, vaso-occlusive crises, psychosocial factors, and sleep continuity. Eighty-three adult patients with SCD completed QST, questionnaires, and daily sleep and pain diaries over a 3-month period, weekly phone calls for 3 months, and monthly phone calls for 12 months. Patients were divided into CS groups (ie, no/low CS [n = 17] vs high CS [n = 21]), on the basis of thermal and mechanical temporal summation and aftersensations, which were norm-referenced to 47 healthy control subjects. High CS subjects reported more clinical pain, vaso-occlusive crises, catastrophizing, and negative mood, and poorer sleep continuity (Ps < .05) over the 18-month follow-up period. Future analyses should investigate whether psychosocial disturbances and sleep mediate the relationship between CS and pain outcomes. PERSPECTIVE: In general, SCD patients with greater CS had more clinical pain, more crises, worse sleep, and more psychosocial disturbances compared with the low CS group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.